4,601 articles
Mezlocillin
Mezlocillin (Mezlin, Baypen, BAY-F-1353) is a semisynthetic ureidopenicillin beta-lactam antibiotic developed by Bayer, FDA approved in 1981, given parenterally for serious gram-negative infections, and discontinued in the U.S.
MGM-16
MGM-16, or 9-fluoro-dihydro-7-hydroxymitragynine, is a semi-synthetic fluorinated kratom-alkaloid derivative and full μ/δ opioid agonist reported in 2014; potent in mouse pain models, never studied in humans, U.S. Schedule I since August 26, 2026.
Mianserin
Mianserin is a tetracyclic antidepressant synthesized in 1966 by Organon in the Netherlands, used for depression and anxiety-related depression, and never approved by the FDA.
Michael Yeadon
Michael Yeadon, retired British pharmacologist, former Pfizer VP and chief scientific officer of allergy and respiratory research (left 2011), Ziarco founder, known for the 2020 Wodarg-Yeadon syncytin-1 vaccine-infertility petition and later COVID-19 denial claims, widely fact-checked.
Miconazole
Miconazole, an imidazole antifungal synthesized by Janssen in 1969, treats candidiasis and dermatophyte infections topically; distinct from other azoles by dual ergosterol and peroxidase inhibition, its intravenous form was withdrawn for vehicle toxicity.
Microdosing
Microdosing: taking subperceptual intermittent doses of psychedelics (LSD, psilocybin) for mood or cognition, or phase 0 subpharmacologic drug testing (1/100 dose, 100 µg max) in humans.
Microspheres
Microspheres: spherical particles from ~20 nm to 1000 μm made of polymers, glass, ceramics, or hydrogels; fabricated by emulsion, spray drying, electrospraying, or microfluidics; used for drug delivery, embolization, diagnostics, and tissue engineering.
Midazolam
Midazolam (Versed) is a short-acting, water-soluble imidazobenzodiazepine synthesized in 1975, FDA-approved in 1985, used for procedural sedation, anesthesia induction, and ICU sedation, with a boxed warning for respiratory depression.
Midostaurin
Midostaurin (Rydapt) is an oral multikinase inhibitor derived from staurosporine, approved in 2017 as the first targeted treatment for FLT3-mutated acute myeloid leukemia and for advanced systemic mastocytosis.
Mifamurtide acid
Mifamurtide (L-MTP-PE, Mepact) is a synthetic NOD2-activating liposomal immunostimulant approved in the EU in 2009 for high-grade resectable non-metastatic osteosarcoma in patients aged 2 to 30.
Migalastat
Migalastat (Galafold, 1-deoxygalactonojirimycin) is Amicus Therapeutics' oral pharmacological chaperone for Fabry disease, approved by EMA 2016 and FDA 2018, for patients with amenable GLA mutations defined by the GLP-HEK assay (≥1.2-fold and ≥3% wild-type alpha-Gal A increase), dosed 123 mg every other day.
Miglitol
Miglitol (Glyset, Diastabol) is an oral alpha-glucosidase inhibitor, a desoxynojirimycin derivative approved by the FDA in 1996, used as adjunct to diet and exercise in type 2 diabetes; dosed 25-100 mg three times daily, renally excreted unchanged.
Miglustat
Miglustat (N-butyldeoxynojirimycin, Zavesca) is an oral glucosylceramide synthase inhibitor, a substrate reduction therapy for type 1 Gaucher disease and Niemann-Pick type C neurological manifestations, and part of Pompe combination therapy.
Milademetan
Milademetan (DS-3032b, RAIN-32) is an oral spiro-oxindole MDM2-p53 interaction inhibitor from Daiichi Sankyo licensed to Rain Therapeutics; its phase III MANTRA trial in dedifferentiated liposarcoma failed, and it remains unapproved.
Milap C. Nahata
Milap C. Nahata is an American pharmacist-scientist at Ohio State whose research made medications safer and better dosed for children, earning the 2024 Remington Honor Medal.
Milvexian
Milvexian (BMS-986177, JNJ-70033093) is an investigational oral, small-molecule, reversible direct factor XIa inhibitor from Bristol Myers Squibb and Janssen; it prevented VTE after knee arthroplasty in phase 2 but failed in the phase 3 LIBREXIA ACS trial.
Minaprine
Minaprine (Cantor) was an aminopyridazine antidepressant acting on serotonergic and dopaminergic transmission, launched 1972 and withdrawn from the French market in 1995 after poison-center data linked its 100 mg tablets to seizures in overdose.
Minimum inhibitory concentration
Minimum inhibitory concentration (MIC): the lowest antimicrobial concentration inhibiting visible microbial growth, measured by broth microdilution (ISO 20776-1, CLSI M07) and interpreted with clinical breakpoints S, I, R.
Minocycline
Minocycline (Minocin) is a semisynthetic second-generation tetracycline antibiotic, FDA-approved 1971, used for acne vulgaris, rosacea (Emrosi 40 mg ER, 2024), and bacterial infections; more adverse effects than doxycycline, including pigmentation and drug-induced lupus.
Minoxidil
Minoxidil, sold as Rogaine, is a vasodilator drug developed in the 1970s for severe hypertension and now best known as a treatment for hair loss.
Mipomersen
Mipomersen, brand name Kynamro, is an antisense oligonucleotide that blocks apoB synthesis, approved in the United States in 2013 for homozygous familial hypercholesterolaemia and since discontinued.
Mirabegron
Mirabegron (Myrbetriq, Betmiga) is a beta-3 adrenergic receptor agonist for overactive bladder, approved in the US in June 2012, recommended by NICE when antimuscarinics fail, with lower dry mouth risk but modest blood pressure increase.
Mirikizumab
Mirikizumab (Omvoh, mirikizumab-mrkz), Eli Lilly's humanized IgG4 antibody against IL-23 p19, treats moderate-to-severe ulcerative colitis and Crohn's disease; first approved in Japan in March 2023 and by the FDA in October 2023.
Mirogabalin
Mirogabalin (Tarlige, DS-5565) is a Daiichi Sankyo gabapentinoid α2δ calcium-channel ligand approved in Japan and other Asian countries for neuropathic pain, with slower α2δ-1 dissociation than pregabalin.
MIRROR study
MIRROR (Mirikizumab Real World Protocol; MIrikizumab in UC - a Real-woRld prOspective multicenteR Registry, NCT06696014) is an observational patient registry sponsored by the University of North Carolina with Eli Lilly, following about 100 adults with ulcerative colitis starting mirikizumab in routine care, with one-year online bowel-habit surveys at nine US and Canadian sites.
Mirtazapine
Mirtazapine (Remeron) is a tetracyclic NaSSA antidepressant approved in the U.S. in 1996; it blocks α2, 5-HT2/5-HT3, and H1 receptors, causing sedation and weight gain, with faster onset than SSRIs.
Mirvetuximab soravtansine
Mirvetuximab soravtansine (Elahere, IMGN853) is a first-in-class antibody-drug conjugate targeting folate receptor alpha, approved for FRα-positive, platinum-resistant ovarian cancer; MIRASOL showed survival benefit over chemotherapy.
Misitatug blivedotin
Misitatug blivedotin (RC88) is RemeGen's mesothelin-targeting antibody-drug conjugate, a humanized anti-MSLN IgG1 linked to MMAE via a cleavable linker, in phase 1/2 trials for ovarian, lung, and cervical cancers.
Misonidazole
Misonidazole (Ro-07-0582) is a 2-nitroimidazole drug developed by Hoffmann-La Roche as a hypoxic-cell radiosensitizer, first given to patients in 1974; toxicity limited its use, though its radiolabeled analog became a PET tracer.
Misoprostol
Misoprostol, a synthetic prostaglandin E1 analog, is used by the FDA for reducing gastric ulcers. Internationally, it is favored for cervical ripening, labor induction, and treating PPH.